Journal Article

Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity

  • Domachowske J
  • Madhi S
  • Simões E
  • et al.
New England Journal of Medicine (2022) 386(9) 892-894
DOI: 10.1056/nejmc2112186
178Citations
Citations of this article
152Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Nirsevimab for Prevention of RSV Nirsevimab is a monoclonal antibody targeting respiratory syncytial virus. In this trial, the safety of nirsevimab was assessed in infants eligible to receive paliv...

Cite

CITATION STYLE

APA

Domachowske, J., Madhi, S. A., Simões, E. A. F., Atanasova, V., Cabañas, F., Furuno, K., … Villafana, T. (2022). Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity. New England Journal of Medicine, 386(9), 892–894. https://doi.org/10.1056/nejmc2112186

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free